Deutsche Bank Sticks to Their Sell Rating for AstraZeneca (AZN)

Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on AstraZeneca today and set a price target of £105.00.

TipRanks Black Friday Sale

• Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
• Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, AstraZeneca, and Sanofi. According to TipRanks, Papadakis has an average return of 3.4% and a 51.69% success rate on recommended stocks.

Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p14,381.85.

Based on AstraZeneca’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p14.84 billion and a net profit of p2.52 billion. In comparison, last year the company earned a revenue of p12.98 billion and had a net profit of p1.93 billion

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.